MLXIPL and fatty liver disease: A 3-week treatment with pentoxifylline aggravated fatty liver in obese diabetic ob/ob mice and this was associated with hepatic ChREBP overactivation, possibly as a consequence of enhanced intestinal glucose absorption and increased postprandial glycemia [105].